Share
Advanced breast cancer: T-DM1 a double whammy against the tumor
Hayette Sénia Bensaber
(Author)
·
Fatima Zohra El Kebir
(Author)
·
Our Knowledge Publishing
· Paperback
Advanced breast cancer: T-DM1 a double whammy against the tumor - Bensaber, Hayette Sénia ; El Kebir, Fatima Zohra
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My Wishlists
Origin: U.S.A.
(Import costs included in the price)
It will be shipped from our warehouse between
Friday, July 26 and
Friday, August 02.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Advanced breast cancer: T-DM1 a double whammy against the tumor"
RESUMET-DM1 is the first of an experimental new cancer drug known as an antibody-drug conjugate. It demonstrates an improvement in progression-free survival over standard therapy in HER2-positive metastatic breast cancer. It combines two existing cancer drugs in order to deliver both drugs specifically to cancer cells: Trastuzumab, a monoclonal antibody to target cells that overproduce the HER2 protein; and, T-DM1 is a chemotherapeutic substance.This is the first ever presentation of an anti-HER2 antibody-drug conjugate used as a primary treatment for patients with advanced breast cancer," said Professor Perez. "We are encouraged by the results. The study explained that T-DM1 has very good anti-tumor activity as well as much lower toxicity when evaluated side-by-side to the older "standard". T-DM1 has displayed promising activity in preclinical studies.
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.
✓ Producto agregado correctamente al carro, Ir a Pagar.
